Company: VERA
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029969
Chunk: 140

Company: Vera Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 140
---
 issued   and outstanding as of December 31, 2024 and 2023

    —

    —

    Class A common stock, $0.001 par value; 500,000,000 shares   authorized as of December 31, 2024 and 2023;    63,559,858 and 44,452,161 shares issued and outstanding as of  December 31, 2024 and 2023, respectively

    64

    44

    Additional paid-in capital

    1,037,948

    410,492

    Accumulated other comprehensive income

    393

    251

    Accumulated deficit

    (461,250
    )

    (309,102
    )

    Total stockholders’ equity

    577,155

    101,685

    Total liabilities and stockholders’ equity
     
    $
    655,681

    $
    175,546

The accompanying notes are an integral part of these financial statements. 

103

VERA THERAPEUTICS, INC. 

Statements of Operations and Comprehensive Loss 

(in thousands, except share and per share amounts) 

    Year Ended December 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    126,172

    $
    78,225

    General and administrative

    40,998

    23,787

    Total operating expenses

    167,170

    102,012

    Loss from operations

    (167,170
    )

    (102,012
    )

    Other income (expense):

    Interest income

    20,714

    7,979

    Interest expense

    (7,626
    )

    (3,786
    )

    Other income, net

    1,935

    1,830

    Total other income

    15,023

    6,023

    Loss before provision for income taxes

    (152,147
    )

    (95,989
    )

    Provision for income taxes

    (1
    )

    (1
    )

    Net loss
     
    $
    (152,148
    )
     
    $
    (95,990
    )

    Other comprehensive income:

    Change in unrealized gains and